Matthew M Seavey Ph.D, MBA
Company: Heat Biologics, Inc.
Job title: VP of Research
Agonizing Over Treg Expansion to Treat Human Disease: An Update on Our TNFRSF25-Agonist, PTX-35 4:00 pm
Describing a clinical-stage Treg immunomodulator with utility in both oncology and auto/inflammation Demonstrating preclinical efficacy in several indications including transplantation, autoimmunity, and metabolic diseases Expanding plans for new indications & modalities – opportunities for partnershipsRead more
day: Day one Track 2 PM
Expert Panel: Optimizing Routes of Administration & Delivery Mechanisms to Induce Timely Treg Specific Activation With 11:30 am
day: Day two track 2 AM